Medicinal cannabis company Zelira Therapeutics Ltd. secured $8.6 million in cornerstone funding from U.S.-based Cantheon Capital LLC that will progress Zelira’s Hope1 cannabinoid medicine to formal phase II/III clinical trials for behaviors associated with autism spectrum disorder.

Fresh off an end-of-year IPO, Coya Therapeutics Inc. is gearing up for clinical testing with its lead Treg-enhancing biologic in neurodegenerative disease, aiming to build on a wealth of academic-generated data highlighting the potential of Treg therapy to attack the neuroinflammation underlying diseases such as amyotrophic lateral sclerosis and Alzheimer’s disease.

Ryne Biotechnology Inc. has been awarded a US$4 million Clinical Stage Research Program (CLIN1) grant by the California Institute for Regenerative Medicine (CIRM) to advance its lead candidate RNDP-001 through IND submission in the next 12 months.

Cerevance Inc. has expanded its series B financing with an additional close of US$51 million, bringing the total series B financing to US$116 million. The proceeds will be used to advance Cerevance's therapeutics for central nervous system (CNS) diseases developed using its proprietary Nuclear Enriched Transcript Sort sequencing (Netsseq) platform.

The occurrence of acute ischemic stroke impacts the immune landscape in the lungs, leading to peripheral immune activation, which can contribute to cerebral reperfusion injury.

Vascular parkinsonism (VP) results from one or more small strokes in the basal ganglia.

Researchers from Merck & Co. Inc. have disclosed the structure and reported preclinical data for MK-8189, a phosphodiesterase 10A (PDE10A) inhibitor.